Circumventing the immunosuppressive microenvironment in cancer therapy, Alabanza et al. in 2022, put forth the innovative concept of ‘armored CAR T cells.’ This design involves engineering CAR T cells to combat TGF-β-induced suppression, a common hurdle in effective cancer treatment. The gene discussed is TGFB1; the disease is cancer.